Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Arix Bioscience plc    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Arix Bioscience : to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

share with twitter share with LinkedIn share with facebook
06/03/2020 | 02:46pm EDT

Arix Bioscience plc

Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

LONDON, 3 June 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, Managing Director, is scheduled to participate in an analyst led fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, 4 June 2020, at 11am EDT/4pm BST.

A live webcast of the fireside chat will be available on the investor relations section of Arix's website at

https://arixbioscience.com/investor-relations/events-presentations. After the conference, an archived replay

will be available on the company's website at the same address.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations +44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com

Disclaimer

Arix Bioscience plc published this content on 03 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2020 18:45:00 UTC

share with twitter share with LinkedIn share with facebook
Latest news on ARIX BIOSCIENCE PLC
07/01ARIX BIOSCIENCE PLC : - Director/PDMR Shareholding, Issue of Ordinary Shares
PR
06/12ARIX BIOSCIENCE PLC : - Aura presents updated AU-011 clinical data at ARVO 2020
PR
06/12ARIX BIOSCIENCE PLC : - Imara presents positive interim Phase 2a data at EHA
PR
06/12ARIX BIOSCIENCE PLC : - Autolus AUTO1 and AUTO3 data at EHA
PR
06/09ARIX BIOSCIENCE : to present at the Proactive One2One Biotech Forum
PU
06/08ARIX BIOSCIENCE : announces strategic and operational update
PU
06/08ARIX BIOSCIENCE PLC : - Arix announces strategic and operational update
PR
06/04ARIX BIOSCIENCE PLC : - Results of Annual General Meeting
PR
06/03ARIX BIOSCIENCE : to Participate in Fireside Chat at the Jefferies Virtual Healt..
PU
06/01ARIX BIOSCIENCE PLC : - Iterum announces topline Phase 3 data in complicated UTI
PR
More news
Financials
Sales 2020 0,50 M 0,62 M 0,62 M
Net income 2020 -24,9 M -31,1 M -31,1 M
Net cash 2020 41,6 M 52,0 M 52,0 M
P/E ratio 2020 -4,51x
Yield 2020 -
Capitalization 113 M 141 M 141 M
EV / Sales 2019
EV / Sales 2020 143x
Nbr of Employees 15
Free-Float 71,2%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 125,50 GBX
Last Close Price 86,50 GBX
Spread / Highest target 45,7%
Spread / Average Target 45,1%
Spread / Lowest Target 44,5%
EPS Revisions
Managers
NameTitle
Jonathan Tobin Co-Managing Director
Christian Schetter Co-Managing Director
Naseem Amin Executive Chairman
Robert Lyne COO, Secretary & General Counsel
Marcus Karia Group Finance Director
Sector and Competitors
1st jan.Capitalization (M$)
ARIX BIOSCIENCE PLC-18.78%141
INVESTOR AB (PUBL)-2.43%40 766
CK HUTCHISON HOLDINGS LIMITED-30.35%25 749
HAL TRUST-12.22%11 851
KOC HOLDING AS--.--%6 438
LIFCO AB (PUBL)4.20%5 810